Home Page : www.otcjournal.com
Email Questions or Comments To:
editor@otcjournal.com
To
OTC Journal Members:
Special Announcement: The
OTC
Journal's Web Site Will Be Down for maintenance over the Thanksgiving
Weekend. You will not see images in your past editions. If you want to
visit the site, you won't be able to get it to come up. It will be back
up prior to the resumption of trading on the 26th.
Also- many apologies for the confusion
in this past weekend's edition- I know the first three paragraphs were
repeated. My mistake- just a formatting error. Someday, when I get really
rich, I'll have an editor on call 24/7.
 |
eFoodSafety
(OTC BB: EFSF) Takes on MRSA Staph |
|
Have you heard of Methicillin-resistant
Staphylococcus aureus- more commonly known at MRSA (pronounce Mersa)
Staph? It's so nasty it can kill you, and it's making the news in a
big way because it is resistant to antibiotics and becoming more widespread.
In October of this year the Center
For Disease Control announced it estimates about 19,000 Americans
die
every year from MRSA Staph. That's about 2,000 more than die of
AIDS. The October edition of the AMA Journal had a feature article which
estimates the are approximately 95,000 cases of MRSA Staph diagnosed
annually.
Two weeks ago, a Texas firefighter-
a very healthy individual, died of MRSA Staph. He was complaining
of back pain, and his doctors failed to diagnose the raging infection until
he had been hospitalized for two days. It was too late. The entire process
from the first doctor's visit to his death took a fleeting two weeks.
MRSA is a resistant variation
of the common bacterium Staphylococcus aureus. It has proven very difficult
to both diagnose and treat. It is often referred to by the media as a "Superbug".
Several newly discovered strains of MRSA show antibiotic resistance
even to vancomycin and teicoplanin (strong antibiotics). These new evolutions
of the MRSA bacterium are very troubling to the medical community.
It's a big problem, and it's spreading.
Today, just after the market opened,
EFSF
made
an announcement which could put some starch back into the price and volume
of EFSF, which has certainly suffered a bit of late. In short, it's
huge stuff, and I hope the market absolutely loves this one, because a
big surge in the stock price is long overdue.
As it turns out, EFSF has
just completed a study which clearly demonstrates its mold eradicating
product, Citroxin, also sabotages the growth of MRSA Staph
with natural ingredients. In a petri dish experiment, Citroxin was
proven to be more effective in killing the MRSA Staph than the antibiotics
that are used to treat patients.
According to the press release, "Citroxin
exhibited a very strong inhibitory effect, far exceeding what other strong
efficacious antibiotics show with inhibition tests for staphylococcus."
For you impatient investors and disappointed
shareholders, this news could be exactly what the doctor ordered. This
could act as the catalyst EFSF needs to get it headed back in the
right direction in a big way.
When January rolls around, it will
mark the one year anniversary of my first edition on EFSF. As you
can easily see from the chart, the first three months were great, but since
then the stock has clearly been a disappointment.
It has nearly given all of its gains
from the first edition when the stock was $.18. The current level
of the stock is fairly reflective of the company's slower than expected
commercialization of its prolific portfolio of products. The market expected
more robust revenues by this point in time- myself included along with
those who had grander expectations.
In the case of EFSF I believe
the odds are with us- why? because they have such a big portfolio of commercially
exciting products- it is inevitable that they eventually will hit it big
on at least one, if not more. Pureffect, Cinnechol, Cinnergen, Oraphtye,
or one unnamed- who knows which one it will or could be? I do know that
each one has "disruptive" potential in its particular space, so the upside
is very promising. Patience is required.
Technically, I can't make any predictions.
Too tough to call. If some major news media outlets pick up on today's
news, investors willing to speculate might learn about this company for
the first time in two or three days, and bid the stock up through the roof.
If it were me, I would want to share this news with the whole world. Buyins.net
claims there should be a 25 million share short squeeze if the stock can
eclipse the $.32 mark. We'll see if we get there- I'd love to find out
if they are right.
Now that you know Citroxin
can kill MRSA Staph, you might want to re evaluate your position
on this company. This is huge, and the market might just love it. Could
be a big day for the stock.
Read the press release for yourself.
For your convenience- today's news from EFSF:
| Press Release Source:
eFoodSafety.com, Inc.
eFoodSafety Announces
Successful Citroxin Lab Tests Against 'Superbug' Eradicating MRSA Strain
of Staph
Tuesday November 20,
9:40 am ET
Biobelt Microbiological Labs Tests
Indicate Citroxin Exhibited a Strong Inhibitory Effect, Exceeding the Results
of What Other Strong Efficacious Antibiotics Show with Inhibition Tests
for Staphylococcus
SCOTTSDALE, Ariz.--(BUSINESS
WIRE)--eFoodSafety.com, Inc. (OTCBB: EFSF - News) announced today that
it has conducted tests, which were successful, using a microbial inhibition
study to determine if Citroxin would eradicate the MRSA bacteria (methicillin
resistant staphylococcus aureus or antibiotic resistant staphylococcus
aureus). The microbial inhibition study is commonly used to determine antimicrobial
effectiveness of antibiotics against known pathogens in a clinical microbiological
setting. Citroxin far exceeded the acceptable level of inhibition against
MRSA than demonstrated by standard antibiotics normally used against non-MRSA
staphylococcus.
MRSA is a particularly
difficult type of staph infection that is causing serious concern for the
nation’s health care system. MRSA is a sub-group that comprises about 40%
of staph bacteria and has become resistant to beta-lactams, antibiotics
normally used to treat staph infections. These include methicillin, amoxicillin,
and penicillin. An antibiotic known as vancomycin has been utilized as
an ace-in-the-hole treatment for these so-called superbugs, but there is
now evidence that these bacterial strains are developing a resistance to
it also. Although there are other antibiotic resistant bacteria, MRSA is
the culprit responsible for most infections. Symptoms of a MRSA infection
can range from mild to severe. A mild staph infection might produce swelling,
redness, fever, and the need for drainage of pus or other fluids from the
site of infection. Symptoms of moderate staph infections may include rash,
high fever, shortness of breath, fatigue, muscle aches, and headaches.
Staph infections that become severe or occur in people with compromised
immunity may cause cellulitis, endocarditis, toxic shock syndrome, blood
poisoning, and pneumonia. If left untreated, organ failure or even death
can occur.
Staphylococcus aureus
(staph) are a common and normally harmless bacteria that live on the skin
and in the nasal passages of about 30% of the population. Staph can cause
an infection when they enter the skin through a cut or sore or enter the
body through a feeding tube or catheter or any other break in the skin.
Normally, MRSA occurs
in hospital settings in “dirty areas,” such as floors, toilets, waiting
rooms, and areas open to hand touch. Proper cleaning is paramount to keeping
infections like MRSA at bay, but one study indicated that even when up
to 90% of a hospital’s wards looked clean, they were in fact only 30-45%
microbially clean.
Biobelt Microbiological
Labs, whose director Kirk Hartwein, a microbiologist, has over 13 years
of experience in doing microbiologic testing for both national and international
firms, conducted the tests resulting in the determination that Citroxin
far exceeded the acceptable level of inhibition against MRSA than typically
demonstrated by standard antibiotics normally used against non-MRSA staphylococcus.
A suspension of MRSA
was prepared and distributed evenly into a Petri dish to create a full
lawn growth (full coverage of MRSA across the dish). After proper incubation,
the Petri dish with MRSA was inoculated with Citroxin. The sample was allowed
to incubate for 24 hours and then studied for inhibitory effect. Determination
was made based on if Citroxin could inhibit MRSA, and if so how far from
the focal point of Citroxin inoculation would this inhibition occur. The
inhibitory effect was dramatic. Citroxin exhibited a very strong inhibitory
effect, far exceeding what other strong efficacious antibiotics show with
inhibition tests for staphylococcus.
Patricia Gruden, President
and CEO of eFoodSafety.com, Inc. stated, “All one has to do to understand
the importance of today’s announcement is turn on the news. MRSA is a particularly
difficult type of antibiotic resistant staph infection that is causing
serious concern for the nation’s health care system. In fact, very recently,
there have been cases of MRSA in schools in Florida and in New York. The
case in New York resulted in the death of a 12-year old boy. Health officials
in New York estimate that there were at least 600 confirmed cases of MRSA
infection last year among school children between the ages of 5 to 18.
In recent years, MRSA has been occurring in seemingly healthy people who
had not been hospitalized. Known as community-based MRSA, these infections
have been showing up in athletes who share equipment like towels, and in
children at school. We’re clearly pleased to now have an objective third
party confirmation of Citroxin’s effectiveness towards battling one of
these new mutations of once easily curable infectious diseases which have
built up immunity to common remedies.”
Citroxin is an environmentally
safe product formulated entirely of food-grade components. In Environmental
Protection Agency (EPA) required laboratory tests, Citroxin showed a 100%
kill rate for the “big six” bacterial health threats: E-coli, Listeria,
Pseudomonas, Salmonella, Staphylococcus, and Streptococcus, as well as
Avian Influenza and Black Mold.
About eFoodSafety.com,
Inc.
eFoodSafety.com, Inc.
is dedicated to improving health conditions around the world through its
innovative technologies. The company’s Knock-Out Technologies, Ltd. subsidiary
has developed an environmentally safe sporicidal product formulated entirely
of food-grade components that eradicates anthrax and a germicidal product,
Citroxin (formerly named Big Six Plus) – EPA Reg. No. 82723-1 that kills
six major bacteria: E-coli, Listeria, Pseudomonas, Salmonella, Staphylococcus,
and Streptococcus, Avian Influenza, and Black Mold. The sporicidal product
has completed its final efficacy laboratory study requisite for EPA registration.
In the study, it eradicated both Clostridium Sporogenes and Bacillus Subtilis
with 100% efficacy on both hard and porous surfaces. The OraPhyte™ product
which has been tested and shown to be effective at eradicating nematodes
by the U.S. Department of Agriculture is currently at three major universities
with outstanding Agricultural Departments undergoing crop-specific research.
The company’s MedElite,
Inc. subsidiary distributes clinically proven products to physicians who
then prescribe the products for their patients. It recently became the
owner of the Talsyn™-CI/bid Scar Cream, that has been clinically proven
to facilitate and improve the appearance, redness and strength of scars
(www.talsyn.com), as well as seven (7) other products in the Talsyn™ line.
The Company is also owner
of Cinnergen™, a clinically-studied, non-prescription liquid whole food
nutritional supplement that promotes healthy glucose metabolism (www.cinnergen.com)
and Cinnechol™, a multi-faceted nutritional supplement specifically designed
to naturally reduce total cholesterol levels without causing any side effects.
The Company has entered into a joint venture agreement with CK41 Direct,
Inc. to launch the PurEffect™ anti-acne skin care system.
Please visit the Company’s
website at: http://www.efoodsafety.com.
Safe Harbor Forward-Looking
Statements
Statements contained
in this release that are not strictly historical are “forward-looking statements.”
Such forward-looking statements are sometimes identified by words such
as “intends,” “anticipates,” “believes,” “expects” and “hopes.” The forward-looking
statements are made based on information available as of the date hereof,
and the Company assumes no obligation to update such forward-looking statements.
Editors and investors are cautioned that such forward-looking statements
involve risks and uncertainties that could cause the Company’s actual results
to differ materially from those in these forward-looking statements. Such
risks and uncertainties include but are not limited to demand for the Company’s
products and services, our ability to continue to develop markets, general
economic conditions, our ability to secure additional financing for the
Company and other factors that may be more fully described in reports to
shareholders and periodic filings with the Securities and Exchange Commission.
Contact:
Redwood Consultants,
LLC
Jens Dalsgaard, 415-884-0348
Source: eFoodSafety.com,
Inc. |
|
